This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock

A new study raises important implications regarding the competitive balance between these two companies.Two pharma juggernauts, Novo Nordisk (NVO 1.64%) and Eli Lilly (LLY 1.53%), are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may be the most lucrative pharmaceutical market to have ever existed. Per some estimates, the weight loss market could be worth around $144 billion by 2030.The m ...